Skip to main content
Offcanvas
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?




Syneos Health Signs Agreement with ACTIVATO to Support Clinical Trials in Japan

January 13, 2025

MORRISVILLE, N.C., JANUARY 13, 2025 - Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, has signed an agreement with ACTIVATO. The agreement expands the Company’s clinical trial capabilities across a broad range of therapeutic areas in Japan.

ACTIVATO now becomes part of the Syneos Health Catalyst and Site Network Partnerships program, including 110+ clinical sites and 60+ commercial site networks. As part of the Site Network Partnerships program,ACTIVATO joins a select set of high-performing investigative site networks strategically aligned to Syneos Health’s clinical studies. Site Network Partnerships provide enhanced patient access, improved efficiencies, specialized expertise and access to diverse patient populations across all therapeutic areas and phases.

“Our venture withACTIVATO is part of our global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Stephane Gouteux,Vice President and General Manager, Japan, Syneos Health.“This collaboration supports our strong focus on customers, achieving consistent delivery and quality for their programs, and executing fit-for-purpose solutions that address their unique and complex needs.”

“Historically, Japanese clinical trials see a relatively larger number of institutions participate in one protocol to satisfy enrollments within a certain period, ultimately placing inevitable burden on sponsors at study initiation. ACTIVATO can offer the independent IRB service in Japan and share its affiliation, including seven AMC networks in Northeast Japan, to reduce burden. Together, Syneos Health and ACTIVATO will jointly promote single IRB and communized ICF to streamline processes from site selection to FPI. We are excited to collaborate with Syneos Health to progress trials in this region,” said Mr. Tomohiko Murao.

“Further, this collaboration will not affect ACTIVATO’S reviewing process. Our trial management office will continue to act independently from the reviewing office, and guide sponsors and sites to streamline and optimize the process and timeline,” added Murao.

About Syneos Health

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.  

We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. 

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.  

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.

Press/Media Contact:                                                  

Meg Byers

Director, External Communications

+1 607 215 1330[email protected] 

Interested in Syneos Health?